AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Cell Genesys collaboration yields $6 million payment from Japan Tobacco.(Brief Article)

Vaccine Weekly

| March 13, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 MAR 13 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) has received a $6 million payment following the completion of a multicenter phase II clinical trial of GVAX lung cancer vaccine from the pharmaceutical division of Japan Tobacco, Inc., (JT) in connection with a worldwide collaboration agreement for GVAX lung cancer vaccines.

Encouraging data from this phase II trial demonstrating anticancer activity in advanced stage lung cancer patients were recently updated at the International Conference on Gene Therapy of Cancer. A phase III trial of GVAX lung cancer vaccine is expected to begin in late 2002.

The data reported in late 2001 were updated clinical results from Cell Genesys' phase II GVAX lung cancer vaccine trial which demonstrated a complete tumor response rate of 12% and a median response duration of at least 11 months in 26 patients with advanced non small-cell lung cancer who have failed chemotherapy and/or radiation therapy. In addition to the responses in patients with advanced disease, eight of the ten patients with early stage lung cancer who received GVAX lung cancer vaccine following surgery, currently remain free of disease with a median follow up time of 12 months.

"We continue to be ...

Related articles from newspapers, magazines, journals, and more
Cell Genesys Announces Initiation of Phase 2 Trial of GVAX(R) Lung Cancer...
Press release article from: PR Newswire June 28, 2004 700+ words
...chief operating officer of Cell Genesys. "Bronchoalveolar lung cancer is generally less responsive...specific GVAX(R) lung cancer vaccines for clinical trials. Cell Genesys is now manufacturing GVAX(R) lung cancer vaccines in its 35,000...
Cell Genesys Confirms Publication of Scientific Paper on GVAX(R) Lung Cancer...
Press release article from: PR Newswire February 20, 2004 700+ words
...clinical trial of Cell Genesys' GVAX(R) lung cancer vaccine trial...of Cancer. Cell Genesys is currently...GVAX(R) lung cancer vaccine to...small-cell lung cancer and is expected...quarter of 2004. Cell Genesys is focused...
Cell Genesys Comments on CBS Segment Highlighting Preliminary Clinical Result...
Press release article from: PR Newswire November 16, 2000 700+ words
...result from Cell Genesys' ongoing Phase...GVAX(R) lung cancer vaccine clinical...is treated. Cell Genesys plans to develop...product for lung cancer since other...participate in Cell Genesys' GVAX(R) lung cancer vaccine trials...
Cell Genesys Advances GVAX(R) Lung Cancer Vaccine To Multicenter Phase I/II...
Press release article from: PR Newswire April 7, 2000 700+ words
...cancers, including lung cancer. Cell Genesys is developing GVAX...in December 1998. Cell Genesys' GVAX(R) lung cancer vaccine is a patient...how to participate in Cell Genesys' GVAX(R) lung cancer vaccine trials can...
Cell Genesys to Start Lung Cancer Vaccine Trial in Memphis, Tenn.
Newspaper article from: The Commercial Appeal (Memphis, Tennessee) (via Knight-Ridder/Tribune Business News) March 6, 2002 700+ words
...That's when Cell Genesys plans to start...for its GVAX lung cancer vaccine from...Stephen Sherwin, Cell Genesys chairman and...26 latestage lung cancer patients for...wonderful benefit." Cell Genesys chose to operate...
Cell Genesys Reacquires Full Commercial Rights to GVAX(R) Lung Cancer Vaccines.
Press release article from: PR Newswire October 18, 2002 700+ words
...International Lung Cancer Congress, Cell Genesys presented the...on GVAX(R) lung cancer vaccines. Under...modified agreement, Cell Genesys would pay JT...for GVAX(R) lung cancer vaccine products. Cell Genesys' GVAX(R...
Cell Genesys Secures Memphis Facility for Manufacturing of Patient-Specific...
Press release article from: PR Newswire February 12, 2002 700+ words
...sets the stage for Cell Genesys' product development...for GVAX(R) lung cancer vaccines which...surgical biopsy. In Cell Genesys' initial Phase II GVAX(R) lung cancer vaccine trial...received GVAX(R) lung cancer vaccine following...of 12 months. ...
Cell Genesys Initiates Second Multicenter Phase I/II Trial of GVAX(R) Lung...
Press release article from: PR Newswire June 21, 2001 700+ words
...operating officer of Cell Genesys. "We are now...both prostate and lung cancer beginning in late...type of vaccine. Cell Genesys is evaluating two...patient-specific lung cancer vaccine one of...manufactured at Cell Genesys. This new format of GVAX(R) ...
For more facts and information, see all results

Source: HighBeam Research, Cell Genesys collaboration yields $6 million payment from Japan...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA